RxDoctor Payments Data

Derek Metoyer, MD

Family Medicine · Opelousas, LANPI 1942384870

Payments from drug & device makers

$467in general payments, 2019–2025

Across 21 payments — averaging $22.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$258
  • Boston Scientific$69
  • Pfizer$57
  • Dexcom, Inc.$49
  • AbbVie$34

What the payments were for

  • Food & beverage$44996%
  • Education$184%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca12$258
Boston Scientific1$69
Pfizer4$57
Dexcom, Inc.2$49
AbbVie2$34

How this compares

$467 in reported general payments places this provider in the 40th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$202,378
Medicare patients
558
Services billed
2,660

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol168$95,802
EliquisApixaban179$94,874
IngrezzaValbenazine Tosylate25$90,884
XareltoRivaroxaban156$77,970
MounjaroTirzepatide71$73,115
OzempicSemaglutide62$58,996
LinzessLinaclotide84$51,578
TrulicityDulaglutide38$41,122
JardianceEmpagliflozin69$38,125
EntrestoSacubitril/Valsartan72$35,978
JanuviaSitagliptin Phosphate41$24,187
CaplytaLumateperone Tosylate24$19,895
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$18,348
TradjentaLinagliptin34$17,962
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen796$13,401

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$258$109,727202 claims
PfizerEliquis$57$94,874179 claims
AbbVieLinzess, Restasis$34$63,630103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Opelousas

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →